Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]-NOTA-hGZP PET Imaging in Healthy Volunteers
NCT05285696Phase 1Completed
- Sponsor
- CytoSite Bio
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium-68 NOTA hGZP in solid tumor, melanoma and non-small cell lung cancer (NSCLC), sponsored by CytoSite Bio. Primary endpoints: Organ-level dosimetry of CSB-111 and total body and effective dose, Percentage of intact CSB-111 in blood samples and 3 more. Started Sep 2022; status: completed.
02
Drugs
gallium-68 NOTA hGZP
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05285696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285696.